2017
DOI: 10.1016/j.parkreldis.2017.02.015
|View full text |Cite
|
Sign up to set email alerts
|

Exploring risk factors for stuttering development in Parkinson disease after deep brain stimulation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
3
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(4 citation statements)
references
References 15 publications
1
3
0
Order By: Relevance
“…This dopamine reduction hypothesis may be consistent with the results from a previous study that provided evidence for a re‐emergence of stuttering in PD . Also, the reduction of levodopa medication dosage following DBS surgery may play a role in the development of post‐DBS stuttering in some IWPD . Perhaps a trial increase in levodopa dosage should be re‐examined in cases of post‐DBS stuttering .…”
Section: Discussionsupporting
confidence: 86%
“…This dopamine reduction hypothesis may be consistent with the results from a previous study that provided evidence for a re‐emergence of stuttering in PD . Also, the reduction of levodopa medication dosage following DBS surgery may play a role in the development of post‐DBS stuttering in some IWPD . Perhaps a trial increase in levodopa dosage should be re‐examined in cases of post‐DBS stuttering .…”
Section: Discussionsupporting
confidence: 86%
“…Syllable repetitions are frequent in PD patients, even though assessment may be complicated by concomitant dysarthria (Hertrich et al, 1994). In addition, deep brain stimulation of either suthalamic nucleus or globus pallidus internus may worsen preexisting childhood onset stuttering, or induce the occurrence of stuttering (Picillo et al, 2017). (3) Neurophysiologically, the balance between inhibitory and excitatory motor intracortical interneurons is tilted in basal ganglia disorders such as Parkinson's disease or dystonia, with less active intracortical inhibitory circuits (Ridding et al, 1995a,b).…”
Section: Introductionmentioning
confidence: 99%
“…Recent studies further demonstrated that DBS is a therapeutic option even in the early stages of PD 6 . However, DBS may exert adverse effects on non‐motor PD symptoms, such as impulsivity, 7 depression, 8 speech fluency, and cognition 9,10 . The mechanisms underlying the DBS‐induced amelioration of PD motor dysfunction and the effects of the combination of DBS with L‐DOPA on the neuronal network are elusive.…”
Section: Introductionmentioning
confidence: 99%